Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose versus no treatment for chemotherapy-associated anemia in multiple myeloma
2009-015766-56Phase 3Completed
- Sponsor
- Vifor Pharma
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in anaemia and multiple myeloma (MM) (2 arms), sponsored by Vifor Pharma. Primary endpoint: Primary efficacy endpoint. Started Oct 2009; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemiamultiple myeloma (MM)
Beyond the preview
Go deeper on 2009-015766-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015766-56.